Contact Us
Drug Search Results
More Filters [+]

Gepotidacin

Alternative Names: gepotidacin, gsk2140944
Latest Update: 2024-11-05
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: TOP2 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Gepotidacin

Countries in Clinic: Australia, Bulgaria, Czech Republic, Germany, Greece, Hungary, India, Japan, Korea, Mexico, Poland, Romania, Slovakia, Spain, United Kingdom, United States

Active Clinical Trial Count: 8

Highest Development Phases

Phase 3: Communicable Diseases|Cystitis|Gonorrhea|Urinary Tract Infections

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
SIS

P3

Recruiting

Communicable Diseases|Urinary Tract Infections|Cystitis

2025-03-19

EAGLE-J

P3

Completed

Urinary Tract Infections|Communicable Diseases|Cystitis

2024-02-02

jRCT2031220467

P3

Recruiting

Cystitis|Urinary Tract Infections

2023-10-31

NCT04010539

P3

Completed

Gonorrhea

2023-10-10

Recent News Events

Date

Type

Title

06/01/2024

PubMed

 The Urinary Microbiome: Improving Diagnostics and Management of Urinary Tract Infections in Adult Females.

05/23/2024

News Article

 New report from Access to Medicine Foundation shows what pharma companies can do to ensure the few promising antimicrobials in development reach patients on the frontlines of drug resistance

05/23/2024

News Article

 New report from Access to Medicine Foundation shows what pharma companies can do to ensure the few promising antimicrobials in development reach patients on the frontlines of drug resistance

05/01/2024

PubMed

 Antimicrobial-resistant Neisseria gonorrhoeae in Europe in 2020 compared with in 2013 and 2018: a retrospective genomic surveillance study.

04/24/2024

PubMed

 In vitro activity of gepotidacin and comparator antimicrobials against isolates of nontuberculous mycobacteria (NTM).

01/24/2024

News Article

 Uncomplicated UTI Treatment Market Expected to Soar to US$11.9 Billion by 2030, By Persistence Market Research

03/30/2023

News Article

 GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions